Form 4: Vaxcyte Director Anne S. Drapeau Reports Stock and Option Awards

Director Anne S. Drapeau reports acquisition of stock and option awards in Vaxcyte, Inc.

Summary

• On June 6, 2024, Anne S. Drapeau, a director of Vaxcyte, Inc. (PCVX), reported the acquisition of 1,550 shares of common stock underlying restricted stock units (RSUs) and an option to purchase 7,250 shares of common stock.
• The RSUs will fully vest on the earlier of June 6, 2025, or the day prior to the next annual meeting of stockholders, subject to acceleration and continuous service.
• The shares subject to the option will vest monthly and fully vest on the earlier of June 6, 2025, or the day prior to the next annual meeting of stockholders, subject to acceleration and continuous service.
• Following these transactions, Drapeau directly owns 7,175 shares of Vaxcyte common stock and options to purchase 7,250 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports routine insider transactions. The acquisition of shares and options by a director can be seen as a mildly positive signal, but it's not a major event.

Positives

• The acquisition of stock and options by a director could be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The vesting schedule of the RSUs and stock options is contingent upon the director's continuous service, aligning her interests with the long-term performance of the company.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. These transactions are closely monitored by investors for insights into management's confidence in the company's prospects.

Stakeholder Impact

• The reported transactions may have a minor positive impact on shareholder sentiment, as they reflect insider confidence.

Key Dates